Aqemia invents novel drug molecules using its QEMI platform, which combines physics-based modeling, statistical mechanics and generative AI to design candidates without experimental data.
Aqemia is a drug invention company that designs entirely new medicines for major unmet medical needs. Rather than refining existing compounds, the firm invents novel molecular entities intended to address diseases that still lack effective treatments. Its work spans pharmaceuticals and biotechnology, covering drug discovery and early drug development.
At the centre of the company is QEMI, a proprietary molecule-invention platform that combines physics-based modeling, statistical mechanics and generative AI. The approach draws on first-principles drug design and de novo molecule design, allowing candidate molecules to be designed without relying on experimental data. This distinguishes the method from conventional computational drug discovery, which typically depends on training from prior experimental results.
Aqemia maintains a growing pipeline of proprietary programs alongside strategic partnerships with leading pharmaceutical companies. Its most advanced programs are preclinical and currently in in vivo optimization.
